BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 [PMID: 29962815 DOI: 10.3748/wjg.v24.i24.2582]
URL: https://www.wjgnet.com/1948-5182/full/v24/i24/2582.htm
Number Citing Articles
1
Myung‐Won You, Kyung Won Kim, Jae‐Jun Shim, Junhee Pyo. Impact of liver‐stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct‐acting antivirals: A systematic review and time‐to‐event meta‐analysisJournal of Gastroenterology and Hepatology 2021; 36(3): 601 doi: 10.1111/jgh.15243
2
Faten Farouk, Ibrahim M. Ibrahim, Salma Sherif, Heba Gamal Abdelhamed, Marwa Sharaky, Ahmed A. Al‐Karmalawy. Investigating the effect of polymerase inhibitors on cellular proliferation: Computational studies, cytotoxicity, CDK1 inhibitory potential, and LC‐MS/MS cancer cell entrapment assaysChemical Biology & Drug Design 2024; 103(3) doi: 10.1111/cbdd.14500
3
Cátia Dias, Filipa Duarte-Ribeiro, Sara Pipa, Ana Rita Barbosa, Margarida Mota, Fernando Rosas Vieira. Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?IDCases 2018; 14: e00450 doi: 10.1016/j.idcr.2018.e00450
4
Wei-Chen Lin, Yang-Sheng Lin, Chen-Wang Chang, Ching-Wei Chang, Tsang-En Wang, Horng-Yuan Wang, Ming-Jen Chen, Chen-Hua Liu. Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinomaPLOS ONE 2020; 15(5): e0233212 doi: 10.1371/journal.pone.0233212
5
Arthi Venkatesan, Febin Prabhu Dass J.. Review on chemogenomic approaches towards hepatitis C viral targetsJournal of Cellular Biochemistry 2019; 120(8): 12167 doi: 10.1002/jcb.28581
6
Ashraf Omar, Ahmed Kaseb, Tamer Elbaz, Mohamed El-Kassas, Amr El Fouly, Abdel Fatah Hanno, Ahmed El Dorry, Ahmed Hosni, Amr Helmy, Amr S Saad, Ashwaq Alolayan, Basem Eysa, Emad Hamada, Hamdy Azim, Hany Khattab, Hesham Elghazaly, Hesham Tawfik, Hisham Ayoub, Hussein Khaled, Ibtessam Saadeldin, Imam Waked, Eman Barakat, Mahmoud El Meteini, Mohamed Hamed Shaaban, Mohamed EzzElarab, Mohamed Fathy, Mohamed Shaker, Mohamed Sobhi, Mohamed Shaker, Mohamed ElGharib, Mohammed Abdullah, Mohesn Mokhtar, Mostafa Elshazli, Omar Heikal, Osama Hetta, Reda ElWakil, Sameh Abdel Wahab, Samir Eid, Yousri Rostom. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular CarcinomaJournal of Hepatocellular Carcinoma 2023; : 1547 doi: 10.2147/JHC.S404424
7
Javeria Khalid, Mohammad Umar, Tofeeq Ur-Rehman, Mashhood Ali, Gul Majid Khan. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapyInfectious Agents and Cancer 2020; 15(1) doi: 10.1186/s13027-020-00300-z
8
I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar. Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antiviralsRevista de Gastroenterología de México (English Edition) 2022; 87(4): 455 doi: 10.1016/j.rgmxen.2021.09.005
9
Mohamad Saeed Marie, Hend Ibrahim Shousha, Wael Abdelrazek, Mohamad Hassany, Hosam Dabees, Reem Abdelghafour, Walaa mosaad Aboganob, Mohamed Said. Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort studyEgyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00247-x
10
Walaa Abdelhamed, Mohamed El‐Kassas. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautifulJournal of Viral Hepatitis 2023; 30(2): 148 doi: 10.1111/jvh.13778
11
Xinhua Zou, Wenzhe Fan, Miao Xue, Jiaping Li. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) ProgressionCancer Management and Research 2021; : 4013 doi: 10.2147/CMAR.S304591
12
Luca Rinaldi, Maria Guarino, Alessandro Perrella, Pia Clara Pafundi, Giovanna Valente, Luca Fontanella, Riccardo Nevola, Barbara Guerrera, Natalina Iuliano, Michele Imparato, Alessio Trabucco, Ferdinando Carlo Sasso, Filomena Morisco, Antonio Ascione, Guido Piai, Luigi Elio Adinolfi. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life ExperienceDigestive Diseases and Sciences 2019; 64(10): 3013 doi: 10.1007/s10620-019-05604-8
13
Maria Guarino, Giovan Giuseppe Di Costanzo, Dario Bruzzese, Anna Sessa, Marco Guarracino, Luca Rinaldi, Andrea Aglitti, Angelo Salomone Megna, Federica Morando, Nicola Coppola, Nicola Caporaso, Filomena Morisco. Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort studyLiver Cancer International 2020; 1(1): 12 doi: 10.1002/lci2.13
14
Martynas Ridziauskas, Birutė Zablockienė, Ligita Jančorienė, Artūras Samuilis, Rolandas Zablockis, Aušrinė Jackevičiūtė. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral DrugsMedicina 2021; 57(3): 210 doi: 10.3390/medicina57030210
15
Altaira D. Dearborn, Joseph Marcotrigiano. Hepatitis C Virus Structure: Defined by What It Is NotCold Spring Harbor Perspectives in Medicine 2020; 10(1): a036822 doi: 10.1101/cshperspect.a036822
16
Johnathan D. Guest, Brian G. Pierce. Structure-Based and Rational Design of a Hepatitis C Virus VaccineViruses 2021; 13(5): 837 doi: 10.3390/v13050837
17
Zobair Younossi, Georgios Papatheodoridis, Patrice Cacoub, Francesco Negro, Heiner Wedemeyer, Linda Henry, Angelos Hatzakis. The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic diseaseJournal of Viral Hepatitis 2018; 25(S3): 6 doi: 10.1111/jvh.13005
18
Salmann Ali, Ammara Naveed, Irshad Hussain, Javaria Qazi. Diagnosis and monitoring of hepatocellular carcinoma in Hepatitis C virus patients using attenuated total reflection Fourier transform infrared spectroscopyPhotodiagnosis and Photodynamic Therapy 2023; 43: 103677 doi: 10.1016/j.pdpdt.2023.103677
19
C Wendy Spearman, Geoffrey M Dusheiko, Margaret Hellard, Mark Sonderup. Hepatitis CThe Lancet 2019; 394(10207): 1451 doi: 10.1016/S0140-6736(19)32320-7
20
Xi Zhong, Tianpei Guan, Danrui Tang, Jiansheng Li, Bingui Lu, Shuzhong Cui, Hongsheng Tang. Differentiation of small (≤ 3 cm) hepatocellular carcinomas from benign nodules in cirrhotic liver: the added additive value of MRI-based radiomics analysis to LI-RADS version 2018 algorithmBMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01710-y
21
Nashwa El‐Khazragy, Amal Ali Elshimy, Safaa Shawky Hassan, Mohamed Hafez Shaaban, Ahmed Hamed Bayoumi, Hekmat M. El Magdoub, Sherief Ghozy, Ahmed Gaballah, Marwa M. Aboelhussein, Hoda H. Abou Gabal, Azzah M. Bannunah, Azza EL‐Sayed Mansy. lnc‐HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct‐acting antivirals therapyMolecular Carcinogenesis 2020; 59(12): 1382 doi: 10.1002/mc.23263
22
Ahmad M. Zidan, Eman A. Saad, Nasser E. Ibrahim, Medhat H. Hashem, Amal Mahmoud, Alaa A. Hemeida. Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infectionHeliyon 2021; 7(5): e06908 doi: 10.1016/j.heliyon.2021.e06908
23
Reina Sasaki, Tatsuo Kanda, Naoya Kato, Osamu Yokosuka, Mitsuhiko Moriyama. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic responseWorld Journal of Hepatology 2018; 10(12): 898-906 doi: 10.4254/wjh.v10.i12.898
24
Ahmed Kamal, Ahmed Elsheaita, Mahmoud Abdelnabi. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debateWorld Journal of Clinical Cases 2022; 10(6): 1764-1774 doi: 10.12998/wjcc.v10.i6.1764
25
Loraine Kay D. Cabral, Luca Grisetti, Muhammad Yogi Pratama, Claudio Tiribelli, Devis Pascut. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting AntiviralsCancers 2022; 14(11): 2700 doi: 10.3390/cancers14112700
26
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT studyHealth Science Reports 2020; 3(2) doi: 10.1002/hsr2.145
27
I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar. Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directaRevista de Gastroenterología de México 2022; 87(4): 455 doi: 10.1016/j.rgmx.2021.03.007
28
Po-Yuan Ke. The Multifaceted Roles of Autophagy in Flavivirus-Host InteractionsInternational Journal of Molecular Sciences 2018; 19(12): 3940 doi: 10.3390/ijms19123940
29
Gamal Shiha, Nasser Mousa, Reham Soliman, Nabiel NNH Mikhail, Mohamed Adel Elbasiony, Mahmoud Khattab. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective studyJournal of Viral Hepatitis 2020; 27(7): 671 doi: 10.1111/jvh.13276
30
Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality checkFrontiers of Medicine 2020; 14(3): 273 doi: 10.1007/s11684-019-0728-2
31
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overviewJournal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
32
Itaru Ozeki, Tomoaki Nakajima, Hirokazu Suii, Ryoji Tatsumi, Masakatsu Yamaguchi, Tomohiro Arakawa, Yasuaki Kuwata. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zincJournal of Clinical Biochemistry and Nutrition 2020; 66(3): 245 doi: 10.3164/jcbn.19-98
33
Akifumi Kuwano, Masayoshi Yada, Shigehiro Nagasawa, Kosuke Tanaka, Yusuke Morita, Akihide Masumoto, Kenta Motomura. Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatmentJournal of Viral Hepatitis 2022; 29(1): 35 doi: 10.1111/jvh.13625
34
Valentina Telatin, Francesco Nicoli, Chiara Frasson, Nicola Menegotto, Francesco Barbaro, Eleonora Castelli, Elke Erne, Giorgio Palù, Antonella Caputo. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral TreatmentFrontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00190
35
Matteo Renzulli, Nicolò Brandi, Giulia Argalia, Stefano Brocchi, Andrea Farolfi, Stefano Fanti, Rita Golfieri. Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesionsLa radiologia medica 2022; 127(2): 129 doi: 10.1007/s11547-022-01449-w
36
Stefania Brozzetti, Marsia Tancredi, Simone Bini, Chiara De Lucia, Jessica Antimi, Chiara D’Alterio, Giuseppe Maria De Sanctis, Caterina Furlan, Vittoria Carolina Malpassuti, Pierleone Lucatelli, Michele Di Martino, Mario Bezzi, Antonio Ciardi, Rosa Maria Pascale. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the ElderlyCancers 2021; 13(12): 3025 doi: 10.3390/cancers13123025
37
Shahab Mahmoudvand, Somayeh Shokri, Reza Taherkhani, Fatemeh Farshadpour. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinomaWorld Journal of Gastroenterology 2019; 25(1): 42-58 doi: 10.3748/wjg.v25.i1.42
38
Shen Li, Antonio Saviano, Derek J. Erstad, Yujin Hoshida, Bryan C. Fuchs, Thomas Baumert, Kenneth K. Tanabe. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational ChallengesJournal of Clinical Medicine 2020; 9(12): 3817 doi: 10.3390/jcm9123817
39
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxì. Hepatitis B Virus-Associated Hepatocellular CarcinomaViruses 2022; 14(5): 986 doi: 10.3390/v14050986
40
Mohammad Enamul Hoque Kayesh, Michinori Kohara, Kyoko Tsukiyama-Kohara. Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An OverviewMicroorganisms 2022; 10(11): 2266 doi: 10.3390/microorganisms10112266
41
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II RecommendationsJournal of Clinical and Experimental Hepatology 2020; 10(1): 43 doi: 10.1016/j.jceh.2019.09.007
42
Kung-Hao Liang, Ming-Wei Lai, Yang-Hsiang Lin, Yu-De Chu, Chih-Lang Lin, Wey-Ran Lin, Ya-Hui Huang, Tong-Hung Wang, Rong-Nan Chien, Tsung-Hui Hu, Chau-Ting Yeh. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patientsBMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01761-1
43
Mohamed Omran, Manar Fouda, Abdelwahab Osama Abdelwahab, Mohamed Mahmoud Nabeel, Ashraf Omar Abdelaziz, Dalia Omran, Hend Ibrahim Shousha. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control studyEuropean Journal of Gastroenterology & Hepatology 2022; 34(2): 220 doi: 10.1097/MEG.0000000000001962
44
Jelena Djokic Kovac, Aleksandar Ivanovic, Tamara Milovanovic, Marjan Micev, Francesco Alessandrino, Richard M. Gore. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlationRadiology and Oncology 2021; 55(2): 130 doi: 10.2478/raon-2021-0004